PATENT/OFFICIAL

Diaket No.: 102258.158US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of

David S. GARVEY et al.

Serial No. 10/628,375 : Group Art Unit:

Filed: July 29, 2003 : Examiner:

For:

CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND

METHODS OF USE

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of any cited U.S. Patents and U.S. Patent Publications are not being submitted in accordance with 37 CFR 1.98(a)(2)(i).

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R.§ 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of

publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The references listed on Sheets 1 - 7 of Form PTO-1449 were cited by or submitted to the U.S. Patent and Trademark Office in related application Serial No. 10/463,671, filed June 18, 2003 and related application Serial No. 10/612,014, filed July 3, 2003.

No fee is believed to be required, however, the Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,

HALE AND DORR LLP

Edward D. Grieff

Registration No. 38,898

1455 Pennsylvania Avenue, NW Washington, DC 20004

TEL 202.942.8400 EDG/mgm

FAX 202.942.8484/

Date:

EXAMINER

INFORMATION DISCLOSURE **CITATION IN AN APPLICATION**

ATTY. DOCKET NO. SERIAL NO. 102258.158US2 10/628,375 APPLICANT David S. GARVEY et al. FILING DATE **GROUP**

3	(PTO-	-1449)	July 29,		GROUP		
		- 8 81	U.S. PATENT DOCUMEN	ITS		- 	1050/15
EXAMINER'S INITIALS PATENT NO		DATE	NAME	CLASS	SUBCLASS		ING ATE
	5,360,925	11/01/94	Chabrier de Lassauniere	et al.		09/29	/93
	5,607,966	03/04/97	Hellberg et al.			12/23	/94
	5,621,000	04/15/97	Arena et al.			05/26	/95
	5,700,947	12/23/97	Del Soldato		•	04/05	/96
	5,703,073	12/30/97	Garvey et al.			10/13	/95
	5,733,909	03/31/98	Black et al.			01/21	/97
	5,780,495	07/14/98	Del Soldato			07/29	/97
	5,789,413	08/04/98	Black et al.			01/21	/97
	5,811,438	09/22/98	Helberg et a.			06/04	/97
	5,849,943	12/15/98	Atkinson et al.		04/07/97		
	5,859,053	01/12/99	Lesur et al.			10/24/97	
	5,861,426	01/19/99	Del Soldato et al.			03/06/97	
	5,925,631	07/20/99	Black et al.			08/03	/98
	6,040,341	03/21/00	Del Soldato et al.			04/29	/98
		FO	REIGN PATENT DOCUM	IENTS			- 5
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Tran Yes	slation No
	EP 0 440 098	08/07/91	Europe			X	<u> </u>
	WO 94/03421	02/17/94	WIPO		1	X	
	WO 94/04484	03/03/94	WIPO			X	
	WO 94/12463	06/09/94	WIPO			X	
	OTH	ER ART (Incl	uding Author, Title, Date,	Pertinent Pages, Etc	c.)		v 8
	Gu, Qu-Ming, C Preparation of (4 No. 16. pp. 176)	hing-Shih Che +)-S-2-(6-Meth 3 – 1766.	n and C. J. Sih. 1986. "A Fa loxy-2-Naphthyl) Propionic	acile Enzymatic Resol Acid (Naproxen)." Te	lution Process tetrahedron Let	ters, Vo	
	oxide from L-arg	ginine." <i>Natur</i>	and S. Moncada. June 16, 1 e, Vol. 333. pp. 664 – 666.				nitric
	MacNaughton, V	Wallace K., Gi	useppe Cirino and John L. W c Oxide) Has Protective Act				5. pp.
	· · · · · · · · · · · · · · · · · · ·		LDATE COL	KOLDEDED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DATE CONSIDERED

SHEET 2 OF 7

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

ATTY. DOCKET NO. 102258.158US2	SERIAL NO. 10/628,375
APPLICANT David S. GARVEY et al.	
FILING DATE	GROUP

(PTO-1449)

	(P1O-	1449)		1 22, 2000				
	14 v. 1. * ·	Ţ	J.S. PATENT	DOCUMENTS	*-			
EXAMINER'S INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS		ING ATE
*	6,043,233	03/28/00	Garvey et al.				01/22	/99
	6,046,191	04/04/00	Hamley et al				10/26	/98
	6,048,858	04/11/00	Garvey et al.				01/22	/99
	6,051,588	04/18/00	Garvey et al.				04/19	/95
	6,057,347	05/02/00	Garvey et al.				09/16	/97
-	6,083,515	07/04/00	Garvey et al.				01/22	/99
	6,143,734	11/07/00	Garvey et al.				01/31	/00
	6,248,745	06/19/01	Hamley et al	•			09/01	/99
	6,297,260	10/02/01	Bandarage et	t al.		·	10/29	/99
	6,323,234	11/27/01	Garvey et al.		03/03	/00		
	2002/0028845 A1	03/01/02	Ekwuribe et	al.	7		03/30	/02
	6,355,666	03/12/02	Lai et al.				06/23	/00
	6,365,184	4/2/02	Depui et al.				12/23/99	
	6,369,260	4/9/02	Sannicolo' e	t al.			5/16/	97
	6,429,223	08/06/02	Lai et al.				11/17	/00
	2002/0111370 A1	08/15/02	Bergman et a	al.			12/20	/01
		FOR	REIGN PATE	NT DOCUMENTS		1.3.0		-30
EXAMINER'S INITIALS	PATENT NO.	DATE		COUNTRY	CLASS	SUBCLASS	Tran	slation
	WO 95/09831	04/13/95	WIPO				X	\vdash
	EP 0 676 204	10/11/95	Europe			<u> </u>	X	┢
	WO 95/30641	11/16/95	WIPO				X	<u> </u>
	WO 96/13483	05/09/96	WIPO				X	
	OTHE	R ART (Inch	uding Author,	Title, Date, Pertine	ent Pages, Etc	.)	1 7 723	9 144-
	Kitagawa, Hisato Relaxing Factor of Experimental The Boughton-Smith, October 23, 1990	, Fumiyo Take on The Gastric erapeutics, Vo Nigel K., Iain . "Protective e	eda and Hiroshi Lesion Induce 1. 253, No. 3. p R. Hutcheson, ffect of S-nitro	Kohei. March 15, 1 d by HCI in Rats." 7	990. "Effect of The Journal of Brendan J. R. amine in endot	of Endotheliun Pharmacology Whittle and Stoxin-induced	and Monce	
	Brown, James F.,	Peter J. Hanse	on, and Brenda	n J. R. Whittle. Oct	ober 13, 1992.	"Nitric oxide		
EXAMINER	increase mucus g	el thickness in	rat stomach."	European Journal of DATE CONSIDER		y, Vol. 223. p	p. 103	<u> – 10</u> .

OFE CATE

EXAMINER

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ATTY. DOCKET NO. SERIAL NO. 102258.158US2 10/628,375

APPLICANT David S. GARVEY et al. GROUP

7	(PTO-	·1449)		July 29, 2003				
		1	U.S. PATENT DO	CUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE	1	NAME	CLASS	SUBCLASS		LING ATE
	6,436,990	08/20/02	Ekwuribe et al.				10/27	700
	6,482,846	11/19/02	Garvey et al.		-		08/30	//01
	6,512,137	01/28/03	Del Soldato et a	<u></u> al.			07/17	/01
	6,525,098	02/25/03	Ekwuribe et al.				10/27	/00
	6,552,078	04/22/03	Ekwuribe et al.				03/30	/01
	2003/0088111	5/8/03	Lai et al.				3/12/0	02
	6,593,347	07/15/03	Bandarage et al				08/27	/01
	10 10 1 year 10 10 10 10 10 10 10 10 10 10 10 10 10	FOI	REIGN PATENT	DOCUMENTS		3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 -		. #
EXAMINER'S INITIALS	PATENT NO.	DATE	Со	DUNTRY	CLASS	SUBCLASS	Trans	slation
	WO 96/32946	10/24/96	WIPO			+	X	\vdash
	WO 97/16405	05/09/97	WIPO			 	X	\vdash
	WO 97/28120	08/07/97	WIPO			†	X	\vdash
	WO 97/28121	08/07/97	WIPO			 	X	\vdash
	WO 97/31654	09/04/97	WIPO				X	\vdash
	WO 97/36863	10/09/97	WIPO				X	
	WO 98/09948	03/12/98	WIPO			1	X	
	WO 98/25981	06/18/98	WIPO				X	
	EP 0 656 881	10/14/98	Europe				X	
	WO 99/44595	09/10/99	WIPO				X	
	WO 99/45004	09/10/99	WIPO				X	
	WO 00/00200	01/06/00	WIPO				X	
			luding Author, Ti					1-1/3
	inflammatory act 40. pp. 176 – 180 Reuter, B. K., G.	tivity and gastr 0. . W. McKnight	rocco, P. Del Solda trointestinal tolerab nt, G. Cirino and J.	L. Wallace. 1993	ac and nitrofens 3. "Nitric Oxid	ac." Agents Act	said	ol.
			estinal Injury or Exa	acerbate Pre-Exis	sting Colitis."	Castagliuoto 1	et al.	
	June 1, 1993. "In	slaw J., Tomas: Inhibition of ni	sz Brzozowski, Jola itric oxide synthase 1. 239. pp. 215 – 21	e delays healing o	nta Pytko-Polor of chronic gast	nczyk and Jerzy ric ulcers." <i>Eur</i>	y Stach	ura.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

DATE CONSIDERED

SHEET 4 OF 7

INFORMATION DISCLOSURE CITATION IN AN APPLICATION ATTY. DOCKET NO.
102258.158US2
10/628,375
APPLICANT
David S. GARVEY et al.

FILING DATE
July 29, 2003

SERIAL NO.
10/628,375
GROUP

(PTO-1449)

	(P10-	1447)				_		
***	Charles Co.		U.S. PATENT DOCUMENTS	<i>5</i> 0 • • • • • • • • • • • • • • • • • • •		4	1	
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS		ING ATE	
To the following following			DESCRIPTION DOCUMENTS			.00		
		FOI	REIGN PATENT DOCUMENT	8				
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Trans	Translation	
HITTALS	TAILM NO.	DAIL	COONINI	02.100	l SCECE ISS	Yes	No	
	WO 00/06585	02/10/00	WIPO			X		
	WO 00/25776	05/11/00	WIPO			X		
	WO 00/44705	08/03/00	WIPO			Х		
	WO 00/51988	09/08/00	WIPO			X		
	WO 00/61537	10/19/00	WIPO			X		
	WO 00/61541	10/19/00	WIPO			X		
	WO 00/61549	10/19/00	WIPO			X		
	WO 00/61604	10/19/00	WIPO			X		
	WO 00/72838	12/07/00	WIPO			X		
	WO 01/00563	01/04/01	WIPO			Х		
	WO 01/04082	01/18/01	WIPO			X		
	WO 01/10814	02/15/01	WIPO			X		
	WO 01/12584	02/22/01	WIPO			X		
	WO 01/49275	07/12/01	WIPO			X		
	WO 01/66088	09/13/01	WIPO			Х		
	OTH	ER ART (Incl	uding Author, Title, Date, Perti	nent Pages, Etc	.)	× 1	27	
	Agents Actions,	Vol. 39. pp. 1	piroxicam, an anti-inflammatory a 58 – 165.				,,,	
	Cuzzolin, Laura	et al 1994. " y Efficacy of l	Effects on Intestinal Microflora, C Diclofenac and Nitrofenac in Adju	Gastrointestinal Tuvant Arthritic R	Folerability and ats." Pharmad	d cologic	al	
	Research, Vol. 2 Rachmilewitz, D Gut, Vol. 35. pp	et al. 1994.	"Enhanced gastric nitric oxide syn	nthase activity in	n duodenal ulce	er patie	nts."	
	Wallace, John L.	et al. March	3, 1994. "A diclofenac derivative . 257. pp. 249 – 255.	without ulcerog	enic properties	." Euro	pear	
EXAMINER	Tournas of Friday		DATE CONSIDE	ERED				

OLD STATE TO STATE OF THE PERSON OF THE PERS

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ATTY. DOCKET NO.	SERIAL NO.
102258.158US2	10/628,375
APPLICANT	
David S. GARVEY et al.	
FILING DATE	GROUP
July 29, 2003	

(PTO-1449)

	(P10-							
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		* 1	U.S. PATENT D	OCUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS		ING ATE
: Ny salamban'i A		FOI	L REIGN PATEN	T DOCUMENT	S		XXXX **	*
EXAMINER'S INITIALS	PATENT NO.	DATE		OUNTRY	CLASS	SUBCLASS	Trans	slation
INITIALS	PATENT NO.	DATE		OUNTRI	CLASS	SUBCLASS	Yes	No
-	WO 01/78781	10/25/01	WIPO				X	
	WO 01/87343	11/22/01	WIPO				X	
	WO 01/93680	12/13/01	WIPO				X	
	WO 02/00166	01/03/02	WIPO				X	÷
	WO 02/00167	01/03/02	WIPO				X	
	WO 02/11706	02/14/02	WIPO				X	
	WO 02/11707	02/14/02	WIPO				X	
110.4.8	WO 02/30866	04/18/02	WIPO				Х	
	WO 02/051385	07/04/02	WIPO				X	
	WO 02/053188	07/11/02	WIPO				X	
	EP 0 904 110	07/24/02	Europe				X	
	WO 02/092072	11/21/02	WIPO				X	
	WO 02/100400	12/19/02	WIPO				X	
	WO 03/000642	01/03/03	WIPO				X	
	WO 03/000643	01/03/03	WIPO				X	
	WO 03/022249	03/20/03	WIPO				X	
	ОТНЕ	R ART (Incl	luding Author,	Γitle, Date, Perti	inent Pages, Etc	.)	Se 9 9	× + 1
	Reuter, Brian K., Toxicity of a Dic	lofenac Deriv	ative." Life Scien	ices, Vol. 55, No	.1. pp. PL-1 - Pl	L-8.		
	Wallace, John L. anti-inflammatory	y drugs." <i>TiP</i> :	S, Vol. 15. pp. 40	05 – 406.				dal ——
	Wallace, J. L., B. inflammatory dru and Hepatology,	igs: A novel a Vol. 9. pp. S	pproach for redu 40 – S44.	cing gastrointesti	inal toxicity." Jos	urnal of Gastro	entero	
	Wallace, John L.	et al. 1994. "	'Novel Nonsteroi	dal Anti-inflamn	natory Drug Deri	vatives With M	1arked	ly
EXAMINER	Reduced Ulcerog	enic Propertie		istroenterology, DATE CONSID		<u>3 – 1/9.</u>		
PVWMMIIIAEK				DATE CONSID				

QE	JC1>>	\\
6	97015	EL C
WE.		AARK
PATEN	T & TP. 49	? /.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ATTY. DOCKET NO. 102258.158US2 10/628,375

APPLICANT David S. GARVEY et al.

FILING DATE July 29, 2003

(PTO-1449)

γ·	(PTO-1449)	July 29, 2003				
	OTHER ART (Including Author, T	itle, Date, Pertinent Pages, Et	c.)			
	Wallace, John L., Quentin J. Pittman and Giusep Novel Class of GI-Sparing Anti-Inflammatory D Theory. Pp. 121 – 129.					
	Wallace, John L., G. Cirino, G. Webb McKnight and Susan N. Elliott. March 21, 1995. "Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester." <i>European Journal of Pharmacology</i> , Vol. 280. pp. 63 – 68.					
	Wallace, John L., Piero Del Soldato and Giusepp Gastrointestinal & Arthritis." Exp. Opin. Invest.					
	Barrachina, M. Dolores et al. June 30, 1995. "Tr inflammatory drug gastropathy." European Jour	ansdermal nitroglycerin preven	ts nonsteroidal anti-			
	Elliott, Susan N., Webb McKnight, Giuseppe Cirino and John L. Wallace. 1995. "A Nitric Oxide-Releas Nonsteroidal Anti-Inflammatory Drug Accelerates Gastric Ulcer Healing in Rats." Gastroenterology, Vo. 109. pp. 524 – 530.					
	Wallace, John L., Webb McKnight, Piero Del Soldato, Anwar R. Baydoun and Giuseppe Cirino. Decen 1995. "Anti-Thrombotic Effects of a Nitric Oxide-releasing, Gastric-sparing Aspirin Derivative." J. Cli. Invest., Vol. 96. pp. 2711 – 2718.					
	Cuzzolin, L. et al. 1995. "Anti-Inflammatory Potency and Gastrointestinal Toxicity of a New Compountion Nitronaproxen." <i>Pharmacological Research</i> , Vol. 31, No. 1. pp. 61 – 65.					
	Langford, E. J., R. J. Wainwright and J. F. Martin. 1996. "Platelet Activation in Acute Myocardial Infarction and Unstable Angina Is Inhibited by Nitric Oxide Donors." Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 16, No. 1. pp. 51 – 55.					
	Del Soldato, P. et al. 1996. "Nitric Oxide-Releasing NSAIDs, A Novel Class of Safe and Effective Anti- Inflammatory Agents." <i>Inflammopharmacology</i> , Vol. 4. pp. 181 – 188.					
	Davies, N. M. et al. 1997. "NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects." <i>Aliment Pharmacol. Ther.</i> , Vol. 11. pp. 69 – 79.					
	Rautio, Jarkko et al. December 1998. "In Vitro Evaluation of Acyloxyalkyl Esters as Dermal Prodrugs of Ketoprofen and Naproxen." <i>Journal of Pharmaceutical Sciences</i> , Vol. 87, No. 12. pp. 1622 – 1628. Endres, Stefan, Andreas Hacker, Eike Noack, Georg Kojda and Jochen Lehmann. 1999. "NO-Donors, p 3: nitrooxyacylated thiosalicylates and salicylates – synthesis and biological activities." <i>Eur. J. Med. Ch.</i> Vol. 34. pp. 895 – 901.					
	Rautio, Jarkko et al. 1999. "Synthesis and In Vit methoxy-2-naphthyl) propionic Acid as Novel N Pharmaceutical Research, Vol. 16, No. 8. pp. 1	aproxen Prodrugs for Dermal I				
EXAMINER		OATE CONSIDERED				
ll .						

SHEET 7 OF 7

OLD E JOINT BROWN

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ATTY. DOCKET NO.

102258.158US2

APPLICANT

David S. GARVEY et al.

FILING DATE

July 29, 2003

SERIAL NO.

10/628,375

GROUP

(PTO-1449) OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) Muscará, Marcelo N., Webb McKnight, Samuel Asfaha & John L. Wallace. 2000. "Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor." British Journal of Pharmacology, Vol. 129. pp. 681 - 686. Bing, Richard J., Tadahiko Yamamoto, Hyunjin Kim and Robert H. Grubbs. 2000. The Pharmacology of a New Nitric Oxide Donor: B-NOD." Biochemical and Biophysical Research Communications, Vol. 275. pp. Al-Swayeh, O. A., R. H. Clifford, P. del Soldato and P. K. Moore. 2000. "A comparison of antiinflammatory and anti-nociceptive activity of nitroaspirin and aspirin." British Journal of Pharmacology, Vol. 129. pp. 343 - 350. Johal, Kamaljit and Peter J. Hoffman. 2000. "Opposite effect of flurbiprofen and the nitroxybutyl ester of flurbiprofen on apoptosis in cultured guinea-pig gastric mucous cells." British Journal of Pharmacology, Vol. 130. pp. 811 – 818. Yamamoto, Tadahiko, N. Rani Kakar, Ernest R. Vina, Paul E. Johnson and Richard J. Bing. 2000. "The effect of aspirin and two nitric oxide donors on the infracted heart in situ." Life Sciences, Vol. 67. pp. 839 -Abadi, Ashraf H., Stefan Laufer and Jochen Lehmann. 2001. "Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2-(6-Methoxy-2-naphthyl) propanoic Acid (Naproxene) Derivatives." Arch. Pharm. Pharm. Med. Chem., Vol. 334. pp. 104 - 106. Gilmer, John F., Louise M. Moriarty, Dermot F. McCafferty and John M. Clancy. 2001. "Synthesis, hydrolysis kinetics and anti-platelet effects of isosorbide mononitrate derivatives of aspirin." European Journal of Pharmaceutical Sciences, Vol. 14. pp. 221 – 227. Kartasasmita, Rahmana E., Stefan Laufer and Jochen Lehmann. 2002. "NO-Donors (VII [1]): Synthesis and Cyclooxygenase Inhibitory Porperties of N- and S-Nitrooxypivaloyl-cysteine Derivatives of Naproxen - A Novel Type of NO-NSAID." Arch. Pharm. Pharm. Med. Chem., Vol. 8. pp. 363 - 366. Cena, Clara et al. 2003. "Antiinflammatory, Gastrosparing, and Antiplatlet Properties of New NO-Donor Esters of Aspirin." J. Med. Chem., Vol. 46. pp. 747 – 754. Wallace, J. L. et al. "Nitric Oxide Releasing NSAID Derivatives: Anti-Inflammatory Without Gastropathy." Gastroenterology, Vol. 106, No. 4., Part 2. Muscará, Marcelo N., Webb McKnight, Samuel Asfaha & John L. Wallace. 2000. "Wound collagen deposition in rats; effects of an NO-NSAID and a selective COX-2 inhibitor." British Journal of Pharmacology, Vol. 129. pp. 681 - 686. **DATE CONSIDERED EXAMINER**